Larvol Delta - OT101-in-Combination-With-Pembrolizumab-in-Subjects-With-Malignant-Pleural-Mesothelioma-Failing-to-Respond-to-Checkpoint-Inhibition

trabedersen (OT-101) - Autotelic, Oncotelic

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT05425576

Jun 21, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next